TDMS Study 96003-03 Pathology Tables
NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a) Report: PEIRPT02
Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01
Route: GAVAGE Time: 09:19:00
FINAL#1/MICE
Facility: BIORELIANCE
Chemical CAS #: 106-95-6
Lock Date: 10/18/00
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include 008 VEHICLE CONTROL
Include 009 0.5 MG/KG
Include 010 1 MG/KG
Include 011 2 MG/KG
Include 012 4 MG/KG
Include 013 8 MG/KG
Include 001 VEHICLE CONTROL
Include 002 0.5 MG/KG
Include 003 1 MG/KG
Include 004 2 MG/KG
Include 005 4 MG/KG
Include 006 8 MG/KG
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a) Report: PEIRPT02
Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01
Route: GAVAGE Time: 09:19:00
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 15 15 15 15 15 15
Early Deaths
Dosing Accident 2
Moribund Sacrifice 2 3 4 6 1 3
Natural Death 2 2 3 1 3
Survivors
Terminal Sacrifice 9 10 8 8 11 12
Animals Examined Microscopically 15 15 15 15 15 15
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (15) (15) (15) (15) (14) (15)
Leukemia Erythrocytic 1 (7%)
Lymphoma Malignant 2 (13%) 1 (7%) 1 (7%)
Salivary Glands (3)
Duct, Carcinoma 3 (100%)
Stomach, Forestomach (14) (15) (12) (13) (14) (15)
Squamous Cell Papilloma 5 (36%) 8 (53%) 4 (33%) 7 (54%) 5 (36%) 6 (40%)
Squamous Cell Papilloma, Multiple 3 (21%) 2 (13%) 2 (17%) 2 (14%) 4 (27%)
Tooth (2) (3) (6) (7) (3) (3)
Odontogenic Tumor 2 (100%) 3 (100%) 6 (100%) 6 (86%) 2 (67%) 3 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (1) (1)
Lymphoma Malignant 1 (100%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (13) (14) (12) (13) (12) (15)
Lymphoma Malignant 1 (7%)
Adrenal Medulla (13) (14) (12) (12) (12) (15)
Lymphoma Malignant 1 (7%)
Pituitary Gland (11) (14) (14) (13) (14) (14)
Lymphoma Malignant 1 (8%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a) Report: PEIRPT02
Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01
Route: GAVAGE Time: 09:19:00
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (13) (15) (14) (14) (13) (15)
Lymphoma Malignant 1 (8%) 1 (7%)
Uterus (13) (15) (13) (14) (12) (15)
Lymphoma Malignant 1 (7%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node, Mesenteric (13) (14) (12) (15) (12) (15)
Lymphoma Malignant 1 (7%)
Lymph Node, Mediastinal (14) (15) (14) (14) (12) (14)
Lymphoma Malignant 1 (7%)
Spleen (15) (14) (15) (15) (13) (15)
Leukemia Erythrocytic 1 (7%)
Lymphoma Malignant 2 (13%) 1 (7%) 1 (7%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (15) (15) (15) (15) (14) (15)
Squamous Cell Papilloma 1 (7%) 1 (7%) 3 (20%) 3 (20%) 5 (36%) 1 (7%)
Squamous Cell Papilloma, Multiple 1 (7%)
Dermis, Fibrosarcoma 1 (7%)
Lip, Squamous Cell Papilloma 1 (7%) 1 (7%) 1 (7%) 3 (20%)
Vulva, Squamous Cell Papilloma 2 (13%) 4 (27%) 1 (7%) 5 (33%) 4 (29%) 6 (40%)
Vulva, Squamous Cell Papilloma, Multiple 1 (7%) 1 (7%) 1 (7%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a) Report: PEIRPT02
Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01
Route: GAVAGE Time: 09:19:00
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (14) (15) (15) (15) (14) (15)
Alveolar/Bronchiolar Adenoma 2 (13%)
Alveolar/Bronchiolar Carcinoma 1 (7%)
Lymphoma Malignant 1 (7%) 1 (7%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1)
Adenoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (15) (14) (14) (15) (13) (15)
Lymphoma Malignant 1 (7%) 1 (7%) 1 (7%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(15) *(15) *(15) *(15) *(15) *(15)
Leukemia Erythrocytic 1 (7%)
Lymphoma Malignant 2 (13%) 1 (7%) 1 (7%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 4
NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a) Report: PEIRPT02
Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01
Route: GAVAGE Time: 09:19:00
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 10 13 10 14 11 14
Total Primary Neoplasms 16 21 19 25 21 27
Total Animals with Benign Neoplasms 9 10 8 9 11 14
Total Benign Neoplasms 12 16 10 18 19 22
Total Animals with Malignant Neoplasms 2 2 3 1 2
Total Malignant Neoplasms 2 2 3 1 2
Total Animals with Metastatic Neoplasms
Total Metastatic Neoplasm
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 2 3 6 6 2 3
Total Uncertain Neoplasms 2 3 6 6 2 3
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 5
NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a) Report: PEIRPT02
Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01
Route: GAVAGE Time: 09:19:00
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS MALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 15 15 15 15 15 15
Early Deaths
Moribund Sacrifice 2 2 3 2 4 1
Natural Death 1 3 3 4 2
Dosing Accident 1 1 1 1
Survivors
Terminal Sacrifice 12 9 9 12 6 11
Animals Examined Microscopically 15 15 15 15 15 15
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (14) (15) (14) (15) (14) (15)
Leukemia Erythrocytic 1 (7%) 1 (7%) 1 (7%)
Salivary Glands (1) (1) (1)
Duct, Carcinoma 1 (100%) 1 (100%) 1 (100%)
Stomach, Forestomach (15) (14) (14) (15) (13) (14)
Squamous Cell Papilloma 5 (33%) 3 (21%) 5 (36%) 5 (33%) 5 (38%) 5 (36%)
Squamous Cell Papilloma, Multiple 1 (7%) 2 (14%) 1 (7%) 1 (7%)
Tooth (5) (5) (4) (3) (6) (4)
Odontogenic Tumor 5 (100%) 5 (100%) 3 (75%) 3 (100%) 6 (100%) 3 (75%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
None
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 6
NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a) Report: PEIRPT02
Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01
Route: GAVAGE Time: 09:19:00
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS MALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
None
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Spleen (15) (14) (14) (15) (14) (15)
Leukemia Erythrocytic 1 (7%) 1 (7%) 1 (7%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (15) (15) (15) (15) (14) (15)
Keratoacanthoma 3 (20%)
Squamous Cell Papilloma 4 (27%) 1 (7%) 5 (33%) 2 (13%) 1 (7%) 1 (7%)
Squamous Cell Papilloma, Multiple 1 (7%) 2 (13%) 1 (7%) 1 (7%) 3 (20%)
Conjunctiva, Squamous Cell Carcinoma 1 (7%)
Lip, Squamous Cell Papilloma 1 (7%) 1 (7%) 1 (7%)
Lip, Squamous Cell Papilloma, Multiple 1 (7%) 1 (7%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (15) (15) (14) (15) (14) (15)
Alveolar/Bronchiolar Adenoma 1 (7%) 1 (7%) 2 (14%)
Alveolar/Bronchiolar Carcinoma 1 (7%)
Carcinoma, Metastatic, Salivary Glands 1 (7%)
Page 7
NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a) Report: PEIRPT02
Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01
Route: GAVAGE Time: 09:19:00
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS MALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Leukemia Erythrocytic 1 (7%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
None
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(15) *(15) *(15) *(15) *(15) *(15)
Leukemia Erythrocytic 1 (7%) 1 (7%) 1 (7%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 8
NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a) Report: PEIRPT02
Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01
Route: GAVAGE Time: 09:19:00
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS MALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 11 10 11 11 12 10
Total Primary Neoplasms 18 14 22 15 17 14
Total Animals with Benign Neoplasms 9 5 9 9 8 7
Total Benign Neoplasms 13 7 17 11 9 10
Total Animals with Malignant Neoplasms 2 2 1 2 1
Total Malignant Neoplasms 2 2 1 2 1
Total Animals with Metastatic Neoplasms 1
Total Metastatic Neoplasm 1
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 5 5 3 3 6 3
Total Uncertain Neoplasms 5 5 3 3 6 3
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 9
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------